Intranasal Antiviral Drug Delivery and Coronavirus Disease 2019 (COVID-19): A State of the Art Review.
Otolaryngol Head Neck Surg
; 163(4): 682-694, 2020 10.
Article
in English
| MEDLINE | ID: covidwho-999410
ABSTRACT
OBJECTIVE:
To provide a state of the art review of intranasal antiviral drug delivery and to discuss current applications, adverse reactions, and future considerations in the management of coronavirus disease 2019 (COVID-19). DATA SOURCES PubMed, Embase, and Clinicaltrials.gov search engines. REVIEWMETHODS:
A structured search of the current literature was performed of dates up to and including April 2020. Search terms were queried as related to topics of antiviral agents and intranasal applications. A series of video conferences was convened among experts in otolaryngology, infectious diseases, public health, pharmacology, and virology to review the literature and discuss relevant findings.CONCLUSIONS:
Intranasal drug delivery for antiviral agents has been studied for many years. Several agents have broad-spectrum antiviral activity, but they still require human safety and efficacy trials prior to implementation. Intranasal drug delivery has potential relevance for future clinical trials in the settings of disease spread prevention and treatment of SARS-CoV-2 and other viral diseases. IMPLICATIONS FOR PRACTICE Intranasal drug delivery represents an important area of research for COVID-19 and other viral diseases. The consideration of any potential adverse reactions is paramount.Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Antiviral Agents
/
Pneumonia, Viral
/
Coronavirus Infections
/
Betacoronavirus
Type of study:
Observational study
/
Prognostic study
/
Reviews
Limits:
Humans
Language:
English
Journal:
Otolaryngol Head Neck Surg
Journal subject:
Otolaryngology
Year:
2020
Document Type:
Article
Affiliation country:
0194599820933170
Similar
MEDLINE
...
LILACS
LIS